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Abstract: Protein–protein interactions (PPIs) control virtually
all cellular processes and have thus emerged as potential
targets for development of molecular therapeutics. Peptide-
based inhibitors of PPIs are attractive given that they offer
recognition potency and selectivity features that are ideal
for function, yet, they do not predominantly populate the
bioactive conformation, frequently suffer from poor cellular
uptake and are easily degraded, for example, by proteases.
The constraint of peptides in a bioactive conformation has
emerged as a promising strategy to mitigate against these li-
abilities. In this work, using peptides derived from hypoxia-
inducible factor 1 (HIF-1a) together with dibromomaleimide
stapling, we identify constrained peptide inhibitors of the
HIF-1a/p300 interaction that are more potent than their un-
constrained sequences. Contrary to expectation, the in-
creased potency does not correlate with an increased popu-
lation of an a-helical conformation in the unbound state as
demonstrated by experimental circular dichroism analysis.
Rather, the ability of the peptide to adopt a bioactive a-heli-
cal conformation in the p300 bound state is better support-
ed in the constrained variant as demonstrated by molecular
dynamics simulations and circular dichroism difference spec-
tra.
Introduction
Protein–protein interactions (PPIs) control virtually all cellular
processes and therefore regulate healthy and disease biol-
ogy.[1–3] For instance, in cancer, overexpression of pro-survival
BCL-2 family proteins attenuates apoptosis supporting surviv-
al,[4, 5] whilst the pattern recognition of toll-like receptors plays
a central role in inflammatory response.[6, 7] Perturbation of PPIs
using synthetic reagents is therefore desirable.[1–3] In some
cases lead discovery campaigns have successfully led to devel-
opment of molecular therapeutics targeting PPIs.[4] In particu-
lar, a-helix mediated PPIs[8] have received attention, in part due
to the defined structural component of binding conferred by
docking of an a-helix from one protein into a cleft on another,
but also as a consequence of the regular pattern of hot-spot
residues that are characteristic of such PPIs.[9–11] This has facili-
tated the development of constrained peptide[12–15] and folda-
mer based[16–18] topological mimics of the helix (i.e. , mimicking
the local conformation of the helix), alongside topographical
mimics[19–23] of the helix (i.e. , mimicking the surface features of
the helix).
Peptide “stapling” has been developed as a versatile method
for targeting a-helix mediated PPIs as well as those mediated
by irregular binding interfaces.[12–15] Constraining a peptide in
an a-helical conformation has been shown to increase peptide
proteolytic stability,[24, 25] improve cellular uptake,[26–28] and en-
hance target binding affinity through pre-organization of the
bioactive conformation,[29, 30] The toolbox for constraining pep-
tides into a bioactive (helical) conformation includes: hydrocar-
bon “staples”,[31, 32] lactam bridges,[33–35] CuI-catalysed azide-
alkyne cycloaddition,[36–40] hydrogen-bond surrogates,[41, 42] and
other chemistries.[43, 44] Adding to this toolbox, the use of,
simple disulfide bridges, crosslinking of (homo)cysteine resi-
dues and other modifications of thiols have been de-
scribed.[15, 45–51] We recently introduced, a stapling protocol that
exploits the reaction of dibromomaleimide[52, 53] with two
(homo)cysteine residues, appropriately placed at i, and i + 4,
positions in the sequence.[49, 54] The approach is versatile, pro-
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ceeds in buffer on unprotected peptides, reversible, and does
not require unnatural amino acids so may in principle be ap-
plied to commercially sourced peptides.
In this work, we apply dibromomaleimide stapling to the de-
velopment of constrained peptide inhibitors of the HIF-1a/
p300 interaction—a promising but challenging target for anti-
cancer drug-development.[55, 56] Using a combination of fluores-
cence anisotropy competition assays, experimental circular di-
chroism and molecular dynamics simulations, we show that
when suitably positioned, introduction of the S,S-maleimide
crosslink within a 14 residue sequence from the C-terminal
region of HIF-1a (residues 812–826) does not lead to a signifi-
cant increase in helicity of the unbound peptide, yet this modi-
fication does increase inhibitory potency. The effect can be ra-
tionalised using molecular dynamics simulations and difference
circular dichroism (CD) spectroscopy, which show that intro-
duction of the constraint in the HIF-1a peptide leads to better
maintenance of the bioactive conformation when bound to
p300. The results highlight the importance of considering the
conformational stability of the bound state in designing con-
strained peptides as inhibitors of PPIs.
Results and Discussion
The HIF-1a/p300 PPI plays a key role in tumour metabolism
and thus represents a promising anticancer target.[55, 56] HIF-1a
is a transcription factor that regulates cellular response to hy-
poxia. When oxygen levels in the tissue are normal, HIF-1a is
degraded rapidly.[57] However, under hypoxic conditions HIF-1a
translocates to the nucleus where it forms a heterodimer with
HIF-1b and this complex recruits the p300 transcriptional coac-
tivator.[58] The hypoxic response cascade results in expression
of multiple genes to relieve oxygen deprivation. As such,
cancer exploits this pathway to resupply oxygen to growing
tumours.[59, 60] The large interaction surface area comprising
three helical regions over which binding free energy is dis-
persed render the HIF-1a/p300 interaction challenging for in-
hibitor identification and design.[55] Epidithioketopiperazine
containing molecules such as Chetomin[61] have been reported
as HIF-1a/p300 inhibitor molecules,[62] however zinc ejection
from p300,[63] has been shown to contribute to the molecular
mode of action, which may lead to nonspecific effects. Several
small-molecules have been identified as potential HIF-1a inhib-
itors whilst a range of constrained peptide and helix mimetic
inhibitors have also been described.[42, 64–66]
Design and synthesis of constrained HIF-1a peptides
HIF-1a binds to p300 by wrapping around it through three
connected helical regions.[67, 68] Amino acids within the second
helix (residues 794–804) and third helix (residues 812–826)
have been identified as important for binding to p300 while
truncation of the third helix, the longest of the helical se-
quences, resulted in attenuation of p300 binding.[41, 65, 69–73] Pre-
viously, our group explored the HIF-1a/p300 PPI interface
using truncated peptides, phage display of linear peptides,
and, non-antibody binding proteins (Affimer).[74] Collectively
these analyses ascertained that the second and third helical re-
gions (HIF-1a794-826) of the 42 residue p300 C-terminal transacti-
vation domain (TAD) were sufficient for p300 binding. These
data informed our choice in this work, to introduce a con-
straint in the third, C-terminal, helix: HIF-1a821–826 (Figure 1).
Cysteine residues were placed at i and i + 4 positions replac-
ing E816 and R820, or E817 and A821 to explore two distinct
stapling locations (Figure 1 a). Alongside the wild-type peptide
(wt), the dibromo maleimide stapled (s), oxidised disulfide (ox)
and reduced thiol (red) peptides for each variant were pre-
pared (Figure 1 b). The peptides were prepared using Fmoc
solid phase peptide synthesis on Rink Amide MBHA resin and
Figure 1. Design and synthesis of constrained HIF-1a peptides as HIF-1a/
p300 inhibitors; a) HIF-1a/p300 NMR solution structure (PDB:1L8C, p300 in
forest green, HIF-1a in cyan) with expansion (right) illustrating helix 3 (resi-
dues 812–826) and residues which were substituted for cysteine and sub-
jected to stapling using dibromomaleimide, b) primary structure of the two
HIF-1a812–826sE816C-R820C and HIF-1a812–826sE817C-A821C dibromomale-
imide stapled variants: primary structures of dibromomaleimide (s), Oxidised
(ox) and reduced (red) together with wild-type (wt) sequence wt-
HIF-1a812–826, c) generic reaction scheme for preparation of dibromomale-
imide stapled peptides and idealised helical conformation adopted as a con-
sequence of stapling.
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capped with acetyl groups at the N-terminus. After purifica-
tion, the peptides were subjected to 30 minutes of stirring
with TCEP to ensure reduction of any disulfide, followed by
the addition of dibromomaleimide for 30 minutes (Figure 1 c),
representing a reduction on the stapling reaction time we de-
scribed in prior work.[49] Fully oxidised (ox) and fully reduced
(red) variants of the peptides were also obtained for biophysi-
cal analyses together with the native sequence.
Biophysical analyses of constrained HIF-1a peptides
The effect of stapling on inhibition of the HIF-1a/p300 interac-
tion was then assessed using fluorescence anisotropy-based
(FA) competition assays. A full-length HIF-1a peptide was used
as the tracer ligand: FITC-Ahx-HIF-1a786–826, Kd = 10.5(4.4) nm
(Figure S1 ESI). None of the HIF-1a812–826 E817C-A821C se-
quences (e.g. , Figure 1 b red staple), was observed to displace
the tracer in the competition assays up to a concentration of
0.9 mm (Figure S2 ESI). This was not unexpected given that
E817 and A821 point towards the p300 protein interface in the
NMR structure of the HIF-1a/p300 complex (Figure 1 a residues
in red); thus a staple at this location likely introduces a steric
clash with the p300 surface. The E817C-A821C series of pep-
tides was thus not studied further although CD analyses indi-
cated minimal differences in helicity across this series of pep-
tides (Figure S3 ESI).
In contrast, the E816-R820 series of peptides comprising
the stapled HIF-1a812–826sE816C-R820C, disulfide bridged
HIF-1a812–826oxE816C-R820C and the reduced thiol
HIF-1a812–826redE816C-R820C peptide gave more interesting re-
sults. The ability of this series of peptides to outcompete the
FITC-Ahx-HIF-1a786–826 tracer in an FA competition assay was
assessed and also compared to the wild-type sequence wt-HIF-
1a812–826 (Figure 2 a). To confirm the peptides were still in their
respective reduced or oxidised states, HRMS data were collect-
ed following the assay (Figure S4 ESI). The wt-HIF-1a812–826 gave
weak inhibition and could not fully displace tracer consistent
with prior results.[74] Similarly, HIF-1a812–826oxE816C-R820C also
showed weak inhibitory potency with an IC50 >600 mm. How-
ever, HIF-1a812–826sE816C-R820C demonstrated considerably im-
proved inhibitory potency with IC50 = 30.3(5) mm (Figure 2).
Unexpectedly, HIF-1a812–826redE816C-R820C, was also shown to
act as an inhibitor of the interaction with an IC50 =
9.9(0.6) mm (see below).
A significant number of studies have shown that introduc-
tion of judiciously placed constraints biases the conformation
of peptides in a helical conformation and this can result in en-
hanced target binding affinity and/or inhibitory potency arising
presumably due to the reduced entropic cost of binding.[12, 13, 29]
Indeed our previous studies on BCL-2 family variant peptides
constrained through maleimide bridging of i and i + 4 bis-
(homo)cysteines demonstrated both enhanced helicity and in-
hibitory potency towards PPIs of MCL-1 and BCL-xL.
[49] To
assess the extent to which preorganization of the peptide
ligand correlated with inhibitory potency, we carried out circu-
lar dichroism analyses on the HIF-1a variant peptides. Surpris-
ingly, the CD spectra (Figure 2 b) showed limited differences
between variants, with all adopting a predominantly random
coil conformation and only HIF-1a812–826sE816C-R820C ([q]MRE-222
6658, 20 % helicity) showing a higher helicity than the other
variants (wt-HIF-1a812826 ; [q]MRE-222 3954, 12 % helicity,
HIF-1a812–826oxE816C-R820C; [q]MRE-222 3766, 11 % helicity,
HIF-1a812 826redE816C-R820C; [q]MRE-222 3375, 10 % helicity).
The difference in helicity between HIF-1a812–826sE816C-R820C
and the other variants is energetically small ; where the binding
mechanism occurs via conformational selection this difference
could make a small contribution to differences in inhibitory po-
tency (see later). We also performed thermal unfolding experi-
ments on the isolated peptides (Figure S5 ESI). The spectrum
of wt-HIF-1a812–826 sequence showed little variation in tempera-
ture. A more significant response was observed for the con-
strained variants, HIF-1a812–826sE816C-R820C, disulfide bridged
HIF-1a812–826oxE816C-R820C indicating greater variation in
structure with increasing temperature.
The shallow inhibitory curve for HIF-1a812–826redE816C-
R820C indicated a non-simple and potentially nonspecific
Figure 2. Biophysical characterization a) FA data for the E816-R820 peptide
series, FITC-Ahx-HIF-1a786–826 tracer (25 nm) p300 (100 nm) 20 mm Tris,
100 mm NaCl 0.1 mm DTT, pH 7.46. b) CD spectra for wt-HIF-1a812–826,
HIF-1a812–826sE816C-R820C, HIF1a812–826oxE816C-R820C and
HIF-1a812–826redE816C-R820C (250 mm concentration, 20 mm sodium phos-
phate, pH 7.55).
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mode of inhibition. We hypothesised that the free thiols may
be detrimental to binding. As such, circular dichroism thermal
denaturation experiments were performed on p300 in isolation
and in the presence of stoichiometric HIF-1a812–826sE816C-
R820C or HIF-1a812–826redE816C-R820C ligands (Figure S6 ESI).
The thermal CD behaviour of p300 with HIF-1a812–826redE816C-
R820C was dramatically different; the sample had a markedly
reduced MRE at 222 nm and minimal differences were ob-
served on increasing temperature (Figure S7 ESI). Such a signif-
icant reduction in p300 helicity upon addition of
HIF-1a812–826redE816C-R820C is consistent with a loss of p300
structural integrity and nonspecific binding, providing an ex-
planation for the observed dose response behaviour. Cheto-
min, a previously discovered HIF-1a/p300 inhibitor,[61] which
contains an electrophilic disulfide was shown to act as a non-
specific inhibitor by zinc ejection[63] whilst several other re-
agents have subsequently been shown to elicit similar nonspe-
cific p300 binding through cysteine modification and/or zinc
ejection.[75] The observation here that bisthiol containing li-
gands can also have nonspecific binding will be the focus of
future studies, nonetheless, this adds to the palate of function-
ality that can confer inherently unselective p300 binding.
Molecular dynamics (MD) analyses and difference circular
dichroisms (CD) of constrained HIF-1a peptides
Given the conformation of the peptides in the absence of
p300 varied minimally, we sought an alternative explanation
for the significantly enhanced potency of FITC-Ahx-
HIF-1a786–826/p300 inhibition by HIF-1a812–826sE816C-R820C in
comparison to the other HIF-1a variant peptides. First, we per-
formed MD simulations of the peptides in solution and in com-
plex with p300 over a 100 ns timeframe (percentage helicities
averaged using the final 50 ns). The MD simulations indicated
that wt-HIF-1a812–826 has a significant helical conformation
(43 %) and moderate increase in helicity (61 %) when in com-
plex with p300 (Figure 3 a). The MD simulation for wt-HIF-
1a812–826 in isolation contrasts somewhat with conclusions ob-
tained from solution CD spectra (Figure 2 b) which indicate lim-
ited population of the helical conformation in isolation. It
should be noted that we use the MD simulations here to pro-
vide a more qualitative evaluation of changes in the preferred
conformation between bound and unbound states, rather
than absolute energetic differences so caution should be exer-
cised in making a direct comparison with the CD data, in par-
ticular between each of the three peptide ligands. The
HIF-1a812–826oxE816C-R820C peptide displayed low helicity
(21 %) and a moderate increase (37 %) when in complex with
p300 about the stapled position (Figure 3 b). Finally, two domi-
nant conformers were observed for HIF-1a812–826sE816C-R820C
over the course of the simulation with the maleimide bridge
oriented in opposing directions with respect to the helix (Fig-
ure 3 d). Both had little helical character (24 % conformer 1 and
29 % conformer 2), with the most helical region observed
across the first six residues of the sequence, in agreement with
the CD data (Figure 3 c). In complex with p300 a more dramat-
ic increase in helicity was observed (56 % and 54 %, respective-
ly) ; both the HIF-1a812–826sE816C-R820C conformers held a heli-
cal conformation propagated over a greater number of resi-
dues in the sequence for a greater portion of the simulation
when compared to the unbound situation. Although constrain-
ed peptides have been shown to have enhanced protein bind-
ing affinity as a consequence of interaction between protein
and staple,[76, 77] that does not appear to be the case here and
instead the results suggest that the higher affinity of
HIF-1a812–826sE816C-R820C arises in part as a consequence of
stabilizing the p300 bound conformation of the peptide
ligand.
To support the MD simulations, we obtained CD difference
spectra. The difference spectra was obtained by subtracting
the additive spectra of the peptide and protein acquired sepa-
rately from a sample containing a mixture of the two com-
bined (Figure 4 a CD data acquired for p300 and
HIF-1a812–826sE816C-R820C). It was reasoned that the difference
between the additive CD signal and the CD signal of the com-
bined sample—where the protein and peptide should be inter-
acting—would offer insight on the influence of p300 on the
conformation of the HIF-1a peptides and reaffirm a binding
event. This difference was plotted as mean residue ellipticity
versus wavelength (Figure 4 b). The experiment was performed
at a concentration of 40 mm, close to the IC50 value for the sta-
pled HIF-1a812–826sE816C-R820C peptide. Firstly, the outcome of
the experiment confirms direct interaction between stapled
peptide and protein target. Secondly, for HIF-1a812–826sE816C-
R820C, the difference spectrum is consistent with an idealized
a-helical conformation with minima at 208 and 222 nm.[78, 79]
The MD simulations do not suggest the constraint makes sig-
nificant non-covalent contacts with p300, whilst conformation-
al changes in p300 that increase helicity in p300 (relative to
the largely helical apo p300) are unlikely to lead to such a sig-
nificant difference in mean residue ellipticity. Therefore, the
substantial increase in MRE in the difference spectra is consis-
tent with a significant increase in helical stability of the pep-
tide ligand in the bound state supporting the conclusions of
the MD simulation. The difference spectrum for the wt-HIF-
1a812–826 is weaker, consistent with the MD simulations that
imply minimal change in helicity upon binding. Lastly, the dif-
ference spectrum for HIF-1a812–826oxE816C-R820C, also indicat-
ed an increase in helicity, however the minima at 204 nm
present for the unbound peptide persisted, suggesting that
this peptide is unable to adopt an idealized and fully helical
conformation in the bound state. Again, these data are consis-
tent with the conclusions of the MD analyses.
Conclusions
In summary we have designed, synthesised and tested S,S
maleimide constrained HIF-1a peptides as HIF-1a/p300 inhibi-
tors. The constrained peptide HIF-1a812–826sE816C-R820C,
showed improved binding affinity but moderate increase in
helicity in the unbound from. In contrast MD simulations were
able to show that the p300 bound form of the peptide adopts
a more stable helix as a consequence of introducing the
staple. The inhibitory potency of the best ligand developed in
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this study (for HIF-1a812–826sE816C-R820C at IC50 30 mm) al-
though greater than one order of magnitude superior to the
wild-type or disulfide variants indicates further optimization
will be required to develop chemical probes. Previously, MD
simulations of eIF4G peptides demonstrated that conforma-
tional constraint with hydrocarbon linkages perturbed the
structural dynamics of peptides when bound or unbound to
eIF4E.[80] These MD simulations revealed that whilst stabiliza-
tion of an unbound peptide in a helical conformation can
readily be achieved, this could adversely affect binding affinity
by favouring metastable conformations that incur a reorganiza-
tional penalty on target engagement, or preventing key side-
chains from adopting the orientation required for binding.
They also demonstrated that the combination of a constraint
and judicious sequence modification promoted solution con-
formations that matched the ideal bound conformation. A re-
lated observation was recently described in studies on con-
strained inhibitors of transcription factor assembly where
subtle changes to structure were observed to affect the stabili-
ty of the bound state.[81] The results presented here for HIF-
1a812–826sE816C-R820C differ; whilst a moderate increase in he-
licity might make a contribution to enhanced p300 binding
and ligand induced changes in p300 conformation cannot be
discounted, our data reveal the potential to enhance target
binding affinity of constrained peptides by explicit stabilization
of a bound conformation (Figure S8). The results add to the
complex effects on molecular recognition that can arise upon
constraining a peptide which include enthalpy-entropy com-
pensation, induced-fit recognition,[82] modulating binding
mechanism and dynamics.[83–86] Thus, our future studies will
focus on collective application of these concepts to a more re-
fined approach for the introduction of constraints in peptide li-
gands, and in particular future further optimization of peptido-
mimetic HIF-1a/p300 inhibitors.
Figure 3. Conformational analyses of HIF-1a812–826sE816C-R820C: a) 100 ns MD simulation of wt-HIF-1a812–826 peptide in the absence (top panel) and presence
(bottom panel) of p300, b) MD simulations of the HIF-1a812–826oxE816C-R820C peptide (panels to the right) in the absence (top panel) and presence (bottom
panel) of p300, c) MD simulations of HIF-1a812–826sE816C-R820C in isolation and in complex with p300 in the two dominant conformations adopted, d) MD
snapshot of two stable p300 bound conformations of HIF-1a812–826sE816C-R820C.
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Solid phase peptide synthesis
General remarks : All amino acids and resins were purchased from
either Novabiochem (Merck) or Sigma–Aldrich. All amino acids
were N-Fmoc protected and side chains protected with Boc (Lys) ;
OtBu (Asp, Ser, Thr) ; Trt (Asn, Gln); Pbf (Arg). Synthesis of all pep-
tides was performed using a microwave assisted automated pep-
tide synthesiser (CEM, Liberty or Liberty Blue). DMF used in peptide
synthesis was of ACS grade and from Sigma–Aldrich. Peptides
were synthesised on an 0.1 mmol scale. Lyophilisation was per-
formed using a BenchTop Pro with OmnitronicsTM from VirTis SP
Scientific. Preparative HPLC was performed on an Agilent Technolo-
gies 1260 infinity controller in conjunction with a diode array de-
tector. Analytical HPLC was performed on an Agilent Technologies
1260 infinity controller in conjunction with a diode array detector.
Mass spectrometry data were obtained on a Bruker MaXis Impact
using electrospray ionisation (ES)MS instruments as appropriate.
Cycles for automated peptide synthesis : Resin loading: Clean re-
action vessel; wash with DMF, wash with CH2Cl2 ; transfer resin to
reaction vessel; wash with DMF, wash with CH2Cl2; vessel draining.
Deprotection and coupling : Clean resin dip tube, wash with DMF
(15 mL) add 20 % piperidine in DMF (6 mL), microwave method
(30 s), wash with DMF (15 mL), clean resin dip tube, wash with
DMF (15 mL), add amino acid (2.5 mL), add coupling reagent
(1 mL), add activator base (0.5 mL), microwave method (5 min),
wash with DMF (15 mL), drain.
For methods that did not use microwave assistance, the reaction
cycle was the same, expect the microwave method for deprotec-
tion and coupling was replaced by agitation of the resin at rt for
10 min and 90 min, respectively.
After the final residue, the resin was ejected from the reaction
vessel and linker coupling, capping, cleavage and deprotection
was performed manually using methods A to B.
For the specific microwave methods used see Supporting Informa-
tion.
Method A : N-terminal acetylation: Acetic anhydride (10 equiv) and
DIPEA (10 equiv) were dissolved in DMF (1 mL) and the solution
was transferred to the resin. After 2 h, the resin was drained,
washed with DMF (3  2 mL  2 min) and successful capping deter-
mined by a negative colour test (Method C).
Method B : Cleavage and deprotection of Rink amide MBHA resin:
After elongation and N-terminal capping was complete, the resin
was washed with CH2Cl2 (5  2 mL  2 min), Et2O (5  2 mL  2 min)
and dried under vacuum for about 2 h. Peptides were simultane-
ously cleaved and side-chain deprotected using Reagent K
TFA:EDT:thioanisole:phenol:H2O 82:3:5:5:5 (3  2 mL  2 h). The so-
lution was precipitated in ice-cold Et2O (25 mL) and placed in a
centrifuge (3000 rpm  10 min), the supernatant removed and the
precipitate resuspended in ice-cold Et2O and placed in a centrifuge
again. This process was repeated 3 or 4 times and the precipitate
was dried under a stream of nitrogen overnight, before being dis-
solved in H2O and lyophilised.
Peptide purification : Crude peptides were suspended in H2O as
concentrated as possible, fractions were checked by LCMS, concen-
trated in vacuo and lyophilised. Peptides were purified by prepara-
tive UV- or MD-HPLC using a Jupiter Proteo preparative column
(reversed phase) on an increasing gradient of acetonitrile in water
+ 0.1 % formic acid (v/v) at a flow rate of 10 mL min1. Crude pep-
tides were suspended in H2O at an approximate concentration of
20 mg mL1. Purification runs injected a maximum of 5 mL of crude
peptide solution and were allowed to run for 30 min, with acetoni-
trile increasing at a stated gradient. In regards to UV-HPLC, the
eluent was scanned with a diode array at 220, 210 and 280 nm. In
regards to MD-HPLC the mass directed chromatography software
Masshunter by ChemStation (Agilent) was used to allow the collec-
tion of the desired peptide by mass, with the eluent split into an
Agilent 6120 Quadropole LCMS which triggers collection of eluent
at a programmed m/z. Fractions containing purified peptide were
combined, concentrated in vacuo and lyophilised.
Fluorescence anisotropy
Fluorescence anisotropy assays were performed in 384-well plates
(Greiner Bio-one). Each experiment was run in triplicate and the
fluorescence anisotropy measured using a Perkin–Elmer EnVi-
sionTM 2103 MultiLabel plate reader, with excitation at 480 nm
(30 nm bandwidth), polarised dichroic mirror at 505 nm and emis-
sion at 535 nm (40 nm bandwidth, S and P polarised). All assays
were performed in 20 mm Tris, 100 mm NaCl 0.1 mm DTT, pH 7.46
Figure 4. CD analysis: a) CD data for the additive (grey), combined (black) and difference spectra (blue) for the HIF-1a812–826sE816C-R820C variant peptide in
the presence of p300. b) Difference CD: spectra for binding of wt-HIF-1a812–826, (black) stapled peptide, HIF-1a812–826sE816C-R820C (blue) and
HIF-1a812–826oxE816C-R820C (green) to p300.
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unless otherwise stated and data analysed following previously
published methods.
The data from both the P (perpendicular intensity) and S (parallel
intensity) channels, resulting from this measurement and corrected
by subtracting the corresponding control wells, were used to cal-
culate the intensity and anisotropy for each well following Equa-
tions (1)–(4):
I ¼ ð2PGÞ þ S ð1Þ
r ¼ ðSPGÞ ð2Þ
Lb ¼ ðrrminÞ=lðrmaxrÞ þ rrmin ð3Þ
y ¼ fðk þ x þ ½FLÞpfk þ x þ ½FL24 ½FLgg=2 ð4Þ
Fluorescence anisotropy data were processed as described previ-
ously.[83]
r = anisotropy, I = total intensity, P = perpendicular intensity, S = par-
allel intensity, G = instrument factor which was set to 1 for all ex-
periments, Lb = fraction ligand bound, l= Ibound/Iunbound = 1, [FL] =
concentration of fluorescent ligand, k = Kd, y = Lb* Flu-trimer and
x = [added titrant], G is an instrument gain factor.
Where I is the total intensity, G is an instrument factor which was
set to 1 for all experiments and r is the anisotropy. The average
anisotropy (across three experimental replicates) and the standard
deviation of these values were then calculated and fit to a sigmoi-
dal logistic model [Eq. (3)] using OriginPro 9.0 which provided the
IC50 and error values: y = rmax + (rminrmax)/(1 + (x/xo) p).
Direct binding assay for FITC-Ahx-HIF-1a786–826 tracer
Fluorescence anisotropy direct titration assays were performed
with protein concentration diluted over 16–24 points using 1=2 dilu-
tions. 20 mL of buffer was first added to each well. 20 mL of a solu-
tion of protein was added to the first column. The solution was
well mixed and 20 mL was taken out and added to the next
column and so on. This operation consists on serial dilution of the
protein across the plate. Finally, 20 mL of tracer was added to the
wells. For control wells, the tracer peptide was replaced with an
identical volume of assay buffer and plates were read after 45 min-
utes.
Competition binding assays
FA competition assays were performed in 384 well plates with the
concentration of peptide competitor typically starting from
850 mm, diluted over 16 points in 1/2 regime with fixed protein
and tracer concentrations. FITC-HIF-1a786–826 was added to each
well to give a final concentration of 50 nm. For control wells, the
tracer peptide was replaced with an identical volume of assay
buffer. The total volume in each well was 60 mL. Plates were read
after 45 minutes of incubation at room temperature.
Circular dichroism
Spectra were recorded on a chirascan circular dichroism spectropo-
larimeter (Applied Photophysics), at 20 8C, using 1 mm cells and a
scan speed of 5 nm min1. The spectra were averaged over three
repeats with a buffer baseline subtracted. Peptide concentrations
of approximately 0.1 mg mL1 were used (although the exact con-
centration was used to allow determination of MME).
p300/peptide spectra and thermal unfolding : Spectra were re-
corded on a chirascan circular dichroism spectropolarimeter (Ap-
plied Photophysics), from 20–90 8C, using 1 mm cells and a scan
speed of 5 nm min1. The spectra were averaged over three repeats
with a buffer baseline subtracted. Protein concentrations of ap-
proximately 0.2 mg mL1 were used (although the exact concentra-
tion was used to allow determination of MME). Peptide concentra-
tions were also of approximately 0.2 mg mL1, in a 1:1 ratio with
the protein. The helical content of protein/peptide complex was
determined from the mean residue ellipticity at 222 nm, [q]
(deg cm2 dmol1) and compared to that of the protein on its own.
p300/peptide difference spectra : Spectra were recorded on a
chirascan circular dichroism spectropolarimeter (Applied Photophy-
sics), at 20 8C, using 10 mm cells and a scan speed of 5 nm min1.
The protein and peptide were each dissolved in buffer and added
to a sample cell, separated by a partition. This prevented the two
solutions from mixing while the CD would acquire a data set
which showed an additive signal of the protein and peptide with-
out these two interacting. Following the CD acquisition of the two
separated solutions, the cuvette was given a shake and the two
solutions mixed. CD spectra was acquired for the mixture. The
spectra were averaged over three repeats with a buffer baseline
subtracted. Each peptide would have three CD traces, one for the
signal in the cuvette where the peptide and protein solution were
separated (no mix), one of the mixed solutions (mix) and the CD
trace of the difference between these two which was calculated by
subtracting the raw data. This CD signals was plotted as mean resi-
due ellipticity [q] (deg cm2 dmol1) versus wavelength.
Molecular dynamics
Model 1 was taken from the PDB structure file 1L8C and the B sub-
unit edited to leave residues L136 to N149 and the resulting pep-
tide capped with N-terminal acetyl and C-terminal amido groups.
Cysteine variations and the maleimide stapled peptides were built
with Chimera v1.13.[87] The protein was parameterised with the am-
ber99SB-ildn forcefield[88] and the staples with GAFF.[89] All simula-
tions were performed using GROMACS v5.1.5[90] using the following
general protocol. Hydrogen atoms were added consistent with
pH 7. The protein was placed in an orthorhombic box 2 nm larger
than the protein in each dimension and filled with TIP3P water
containing 0.15 m sodium chloride ions to give a charge-neutral
system overall. After 10 000 steps of steepest descent minimisation,
molecular dynamics was initiated with random velocities while re-
straining the protein backbone to its original position with a force
constant of 1000 kJ nm1 for 0.2 ns. Simulations were developed
for a further 100 without the backbone position restraints under
periodic boundary conditions. The Particle Mesh Ewald’s method
was used for long range electrostatic interactions while short
range Coulombic and van de Waals energies were truncated at
1.4 nm. The temperature was maintained at 300 K using the v-re-
scale method and the pressure at 1 bar with the Berendsen baro-
stat and a 2 fs time step for the leapfrog integrator. Bond con-
straints were implemented with the LINCS method and SETTLE
used for waters. Trajectories were processed and analysed with the
GROMACS tools and visualised with VMD 1.9.3.[91]
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Inhibitors: Helicity Enhancement in
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Potency
Hold tight : S,S-Maleimide constrained
HIF-1a peptides are shown to be more
potent inhibitors of the HIF-1a/p300 in-
teraction than their unconstrained
counterparts due to stabilization of the
bioactive conformation when bound to
p300, as demonstrated by molecular dy-
namics simulations and difference circu-
lar dichroism (CD) spectroscopy.
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